COMMUNIQUÉS West-GlobeNewswire

Vivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross Proceeds
15/02/2024
LITTLETON, Colo., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and [...]
Extendicare Announces February 2024 Dividend of C$0.04 per Share
15/02/2024
MARKHAM, Ontario, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.04 per common share of the Company (the “Common [...]
Vaccinex, Inc. Announces Reverse Stock Split
15/02/2024
ROCHESTER, N.Y., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc., (NASDAQ: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the [...]
Indaptus Therapeutics to Present at the 2024 BIO CEO & Investor Conference
15/02/2024
NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announced today [...]
Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS
15/02/2024
Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS High-dose frexalimab significantly reduced disease activity, demonstrating 89% reduction in new brain lesions Phase 3 [...]
Communiqué de presse : Des données de phase II publiées dans le NEJM illustrent le fort potentiel d’efficacité du frexalimab dans le traitement de la sclérose en plaques récurrente-rémittente
15/02/2024
Des données de phase II publiées dans le NEJM illustrent le fort potentiel d’efficacité du frexalimab dans le traitement de la sclérose en plaques récurrente-rémittente Le frexalimab à dose élevée a permis de réduire [...]
Spectral Medical Announces Major Milestone by Reaching Its Interim Enrollment Target of 90 Patients
15/02/2024
TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced a [...]
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
15/02/2024
WARMINSTER, Pa., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for [...]
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis
15/02/2024
Collaboration combines Intellia’s leading CRISPR-based platform, including its DNA writing technology, with ReCode’s proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) to extend the reach of gene [...]
Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
15/02/2024
Study milestone further extends momentum for Company’s lead PDC candidate and oncology clinical development program MONTREAL, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company [...]
Theratechnologies complète le recrutement des six premières patientes de l’essai clinique de phase I mis à jour sur le sudocétaxel zendusortide dans le traitement du cancer de l’ovaire avancé
15/02/2024
Une étape importante de l’étude afin de poursuivre l’élan pour le principal CPM de la Société et son programme de développement clinique en oncologie MONTRÉAL, 15 févr. 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc [...]
Avicanna Announces New Research Collaboration with a Multi-national European-based Pharmaceutical Company
15/02/2024
Research will assess the combination of Avicanna’s proprietary SEDDS technology in various drug delivery systems and dosage forms TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company [...]
Bitech Technologies Completes Due Diligence on BESS Projects to Prepare for a Business Combination
15/02/2024
Newport Beach, CA, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Bitech Technologies Corporation [ OTCQB: BTTC ], (“the Company” or “Bitech”) a global technology solution provider dedicated to green energy solutions, is pleased to [...]
Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024
15/02/2024
LONDON and SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (the “Company”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical [...]
Sotera Health Announces Fourth-Quarter and Full-Year 2023 Earnings Release Date
15/02/2024
CLEVELAND, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare [...]
Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22
15/02/2024
WATERTOWN, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein [...]
Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024
15/02/2024
PRINCETON, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, February 28, 2024, at 8:30 a.m. ET [...]
Widmer Brothers Brewing’s Beloved White Gold Hazy Lager Returns
15/02/2024
Generations In the Making, This Hazy Golden Wheat Lager Balances the Scales With Elegance of Flavor Both Crisp and Smooth PORTLAND, Ore., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Widmer Brothers Brewing (“Widmer Brothers”) , [...]
Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
15/02/2024
– Announced Positive Results from the Phase 3 ENERGIZE Study of Mitapivat in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia – – Presented Positive Results from Phase 2 Portion of the RISE UP Pivotal [...]

Pages